Group items tagged

With conventional corticosteroid treatment being effective in only 50-60% of patients, development of new treatment options is necessary to cover the unmet needs of the uveitis market. The market is currently dominated by corticosteroid treatment options and off-label immunosuppressive and biologic drugs. Although anterior uveitis patients constitute the major share of patients, except one, all the new treatments in late stage clinical development target the intermediate, posterior and pan uveitis patient segment. Drugs capable of permanently inhibiting ocular inflammation as well as offering an improved safety profile will have a significant impact on the uveitis market.

One of the main drivers propelling the growth of the market for drugs used to treat patients with Parkinson's disease is the steadily growing aging population worldwide. This is because the number of patients suffering from Parkinson's disease is increasing owing to the rise in aging population both in the developing as well as developed nations. One of the major challenges to market growth is the weak pipeline landscape. Most products in the pipeline lack molecules that can potentially achieve blockbuster status in the near future.

Diabetic foot ulcers (DFUs) are a common complication of diabetes. With the increasing prevalence of diabetes across all markets the number of patients suffering from DFUs is also expected to rise. The global DFU therapeutics market is set to enter an exciting phase with the potential launch of three wound-healing agents in the next five years. The first two topical antibacterial are also expected to be launched in the US and the five major EU markets. With the advent of these new product launches, the size of the DFU market is expected to grow substantially by 2017.

The non-existence of effective vaccine against HCV leads the healthcare market in United States to be driven by therapeutics. Vertexs Incivek was amongst the first DAA HCV therapies launched in the US and is the current market leader. Inciveks improved efficacy over the previous standard of care in the treatment of the most prevalent HCV genotype in the US, HCV GT1, which enabled the drug to quickly capture the market. Adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.

According to diagnostic ultrasound imaging market forecasts, the global disease incidence is expected to rise and an early diagnosis of disease is the foundation for increasing survival rates. Diagnostic ultrasound imaging is the most widely used technique to achieve early detection and clinical assessment of adult and pediatric patients alike, making it a cornerstone of disease control. In the diagnostic ultrasound imaging market landscape GE Healthcare currently dominates the global diagnostic ultrasound market.

The rapidly growing healthcare market in India continuously drives the demand for medical devices. Research on medical device market unveils that the booming Indian economy is witnessing a tremendous surge in the domestic healthcare scenario which, in turn, is leading to perpetual demand for high quality medical products. The demand for high-end, quality devices is especially driven by the private healthcare sector in its efforts to provide sophisticated treatment to patients.